Fredun targets 25-30% growth in FY27, eyes ₹100 cr mobility run rate
Transcript details plans for hormonal therapies, anti-aging, and pet care platform Wagr; management targets PAT margins of 10-12% in medium term.
— 5 earlier stories on Fredun Pharmaceuticals Ltd. →What's new
- Plans to enter hormonal therapies and anti-aging with first/second-in-India products.
- Pet care division to launch Wagr platform in July; earned ₹42-43 cr in FY26.
- Mobility revenue of ₹30 cr set to reach ₹100 cr run rate within 2.5 years.
Why this matters
Fredun is pivoting from generic pharma to higher-margin consumer and mobility verticals. The 10-12% PAT margin target implies a significant improvement from current profitability levels, supported by the mix shift. If achieved, the stock's 38.9x P/E could find justification in earnings acceleration.
What we're watching
- Wagr platform traction and revenue contribution post-July launch.
- Regulatory clearances and market entry for hormonal/anti-aging products.
- Quarterly mobility revenue trajectory toward ₹100 cr run rate.
The full read
Fredun's earnings call transcript fleshes out the pivot outlined in the June 10 concall. The new details are concrete: entry into hormonal therapies and anti-aging with first- or second-in-India products, a July launch for the pet care platform Wagr, and a mobility target of ₹100 crore run rate within 2.5 years from the current ₹30 crore. The growth guidance of 25-30% for FY27 matches the trailing 27% revenue growth, but the real story is whether margins improve as new businesses scale. Management is targeting a PAT margin of 10-12% in the medium term, betting that higher-margin consumer and mobility businesses will lift profitability from current levels. The 10-12% target implies a significant improvement over the trailing ROE of 11.7%. If execution holds, a 38.9x P/E may prove justified. The risks are regulatory timelines and consumer adoption, but the direction is clear.
Questions answered
- What is Wagr, and why does it matter?
- Wagr is a pet care platform launching in July. It represents Fredun's push into direct-to-consumer branded products, which carry higher margins than contract manufacturing.
- How large is the pet care business currently?
- The pet care division generated ₹42-43 crore in revenue during FY26, providing a base for the Wagr launch.
- What are the margin improvement drivers?
- Management cites higher margins from new-age businesses (pet care, mobility, anti-aging) and is targeting a PAT margin of 10-12% in the medium term, up from an ROE of 11.7% on trailing basis.
- Is the 25-30% revenue growth guidance consistent with past performance?
- Yes, trailing revenue growth was 27.3%, so the guidance is in line and represents continuation of the recent trajectory.
- When will the mobility business reach a ₹100 cr run rate?
- Management expects the mobility vertical, which currently generates ₹30 crore, to hit a ₹100 crore run rate within 2.5 years.
Fredun Pharmaceuticals Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on FREDUN →- 12 Jun 2026 · 7:30 PM IST Fredun targets 25-30% growth in FY27, eyes ₹100 cr mobility run rate
- 2d ago Fredun pivots to pet care and physiotherapy, guides 25-30% revenue growth for FY27
- 18d ago Fredun Pharmaceuticals posts 60% profit jump and declares 2:1 bonus
- 18d ago Fredun Pharmaceuticals lifts profit 60% and declares 2:1 bonus
- 18d ago Fredun Pharma's profit jumps 60%, declares 2:1 bonus